Signature Odor of Parkinson's Disease Discovered
By LabMedica International staff writers Posted on 02 Apr 2019 |
Image: The 5977B High Efficiency Source (HES) GC/MSD System (Photo courtesy of Agilent Technologies).
Parkinson's disease is a neurodegenerative disorder that leads to progressive brain cell death and extensive loss of motor function. Despite many investigations being conducted on this disease, there are no definitive diagnostic tests currently available.
Volatile organic compounds (VOCs) are often associated with characteristic odors, although some volatiles may also be odorless. The term “volatilome” describes the entirety of the volatile organic and inorganic compounds that may originate from any organism, or object, which may be analytically characterized.
A team of biochemists and other scientists working with the University of Manchester (Manchester, UK) collected sebum samples, an oily or waxy matter secreted by sebaceous glands, using gauze to swab the upper backs of more than 60 subjects, both with and without Parkinson's disease (PD). There were 43 PD subjects and 21 controls, and an independent validation cohort of 31.
A dynamic headspace (DHS) gas chromatography–mass spectrometry (GC–MS) method was developed for the analysis of gauze swabs, which contained sampled participant sebum. DHS is a sample preparation capability for subsequent GC application using the GERSTEL MultiPurpose sampler that concentrates VOCs from liquid or solid samples. The GC analysis was performed on an Agilent GC 7890B coupled to an Agilent MSD 5977B.
The team showed that the data revealed the presence of hippuric acid, eicosane and octadecanal, which indicate the altered levels of neurotransmitters found in Parkinson's patients, along with several other biomarkers for the disease. There were no significant differences observed between PD participants on medication and drug naïve PD participants for all measured volatiles, indicating that the majority of the analyzed volatilome and by inference sebum are unlikely to contain drug metabolites associated with PD medication.
The authors concluded that their study highlights the potential of comprehensive analysis of sebum from PD patients and raises the possibility that individuals can be screened noninvasively based on targeted analysis for these volatile biomarkers. The study was published on March 20, 2019, in the journal ACS Central Science.
Related Links:
University of Manchester
Volatile organic compounds (VOCs) are often associated with characteristic odors, although some volatiles may also be odorless. The term “volatilome” describes the entirety of the volatile organic and inorganic compounds that may originate from any organism, or object, which may be analytically characterized.
A team of biochemists and other scientists working with the University of Manchester (Manchester, UK) collected sebum samples, an oily or waxy matter secreted by sebaceous glands, using gauze to swab the upper backs of more than 60 subjects, both with and without Parkinson's disease (PD). There were 43 PD subjects and 21 controls, and an independent validation cohort of 31.
A dynamic headspace (DHS) gas chromatography–mass spectrometry (GC–MS) method was developed for the analysis of gauze swabs, which contained sampled participant sebum. DHS is a sample preparation capability for subsequent GC application using the GERSTEL MultiPurpose sampler that concentrates VOCs from liquid or solid samples. The GC analysis was performed on an Agilent GC 7890B coupled to an Agilent MSD 5977B.
The team showed that the data revealed the presence of hippuric acid, eicosane and octadecanal, which indicate the altered levels of neurotransmitters found in Parkinson's patients, along with several other biomarkers for the disease. There were no significant differences observed between PD participants on medication and drug naïve PD participants for all measured volatiles, indicating that the majority of the analyzed volatilome and by inference sebum are unlikely to contain drug metabolites associated with PD medication.
The authors concluded that their study highlights the potential of comprehensive analysis of sebum from PD patients and raises the possibility that individuals can be screened noninvasively based on targeted analysis for these volatile biomarkers. The study was published on March 20, 2019, in the journal ACS Central Science.
Related Links:
University of Manchester
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines